DAVID LONARD to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications DAVID LONARD has written about Xenograft Model Antitumor Assays.
Connection Strength
0.740
-
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents. Endocr Relat Cancer. 2021 08 13; 28(10):657-670.
Score: 0.576
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
Score: 0.043
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
Score: 0.035
-
Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocr Relat Cancer. 2020 04; 27(4):209-220.
Score: 0.033
-
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.
Score: 0.030
-
Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10; 28(2):240-52.
Score: 0.024